Health Care : Current Reviews

Overview of the economic opinions published by the HAS in 2022

9^th World Congress on Health Economics, Health Policy and Healthcare Management

April 17-18, 2023 | Paris, France

Bertrand Tehard*, Clea Sambuc, Fabienne Midy, Julie Chevalier and Stephane Roze

Vyoo Agency, France

Posters & Accepted Abstracts: Health Care Curr Re

Abstract:

In France, the CEESP (Economic & Public Health Assessment Commission) oversees health economic appraisal of medical technologies when requested concomitantly with a reimbursement demand. This appraisal establishes the methodological acceptability of the health economic dossier submitted. Methodological acceptability is defined through methodological reservations qualified as minor, important or major. A major reservation invalidates the dossier and the economic value that it defends. An appraisal also specifies the level of uncertainty surrounding the results. A major uncertainty invalidates the results and the dossier per se. Uncertainty could be driven by the difficulty to estimate key parameters, by a lack of credibility of hypotheses or interpretability of the results. Using Vyoo Agency efficiency database, the objective is to analyze the main reasons retained by the CEESP to invalidate the economic information among health economic appraisals published in 2022. All available Health Economic appraisals published between January 1 and until December 31, 2022, were reviewed. In 2022, 27 appraisals were disclosed, 14 of which were invalidated. Thirteen major methodological reservations were stated, invalidating 9 dossiers. The major reservations relate to relative effectiveness modelling (6), utility estimation (5) and sensitivity analyses (2). Relating to the modelling of the treatment effect, 3 reservations concern indirect comparisons and 3 hypotheses used to model the relative effect regarding available data. In addition, 4 dossiers were invalidated due to major uncertainty mainly supported by the evolving context (2), statistical variability of the parameters (1) or immaturity of the data (1). One evaluation was not assessable. In 2022, less than 50% of dossiers are likely to provide valuable economic information in the decision-making process in France. Reducing the number of invaluable assessments is a key issue to ensure economic information can be fully used in price negotiations.

Biography :

Bertrand has a PhD in Epidemiology/Biostatistics and a degree from the Institute of Statistics and the University of Paris. He has 20 years of experience in epidemiological studies and health economic evaluations with a university (INSERM), institutional (INCa) and pharmaceutical industry background. He has participated in many efficiency dossiers submitted to the CEESP and is teaching student of Master degree of Market Access and Health Economic Evaluation in Chatenay-Malabry. He has an expertise in model development in oncology.